PI3 Pathway
![]()
PI3-K/AKT signalling regulates cellular processes such as proliferation, growth,
survival, apoptosis, and the upregulation of hypoxia-related proteins. Activation of
this pathway involves various receptor tyrosine kinases, such as Insulin or IGFR1 or
cytokines to name a few. DiscoveRx offers novel, non-imaging , cell-based and
biochemical assays to study various aspects of the PI3 Pathway. Ready to screen,
biosensor cell lines allows you to study receptor activation, phosphorylation or
downstream foxo translocation in a HTS-friendly cell-based format, while universal,
non-antibody ADP accumulation assay provides a screening-friendly in-vitro assay
format, for identifying PI3 or AKT inhibitors.
PathHunter® FOXO Translocation assay
The PathHunter assay monitors the interaction of two proteins in a whole cell, homogeneous assay format using enzyme fragment complementation. The cells have been engineered to express two complementing fragments of β-Gal within different cellular compartments. In this system, a small 42 AA enzyme fragment, Read More»
Product Features
Novel cell-based assay that measures downstream FOXO translocation
Whole cell, chemiluminescent assay
Single addition, HTS-friendly format
Applications
Assay serves as PI3-kinase pathway indicator
Allows for Screening of inhibitors for PI3-kinase and Akt
A tool for studying molecules affecting FOXO3 nuclear translocation
Biochemical assay
for PI3/AKT inhibitors
Available Literature
Click here to view what we have available!
New! Custom bulk cell options are available with the purchase of any (PathHunter® Cell-Based Kinase) clone. Package sizes range from 100 million to 2 billion cells. Frozen, assay-ready bulk cells will expedite your screening campaigns and ensure reproducible results. Bulk cells are functionally tested for optimal assay performance and are confirmed to be Mycoplasma-free. Click here for a quote.
Don't see your target?
Click here to explore our Custom Assay Development possibilities.
Copyright ©2009, DiscoveRx Corporation. TERMS AND CONDITIONS
0